Clinical utility of telavancin for treatment of hospital-acquired pneumonia: Focus on non-ventilator-associated pneumonia

Infection and Drug Resistance

Volumn 7, Issue , 2014, Pages 129-135

  Rubinstein, Ethan ^a   Stryjewski, Martin E ^b   Barriere, Steven L ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CEMIC   (Argentina)

^c THERAVANCE INC   (United States)

Author keywords

Methicillin resistant Staphylococcus aureus; Nosocomial pneumonia; Staphylococcus aureus

Indexed keywords

TELAVANCIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; AGED; BACTERIUM ISOLATION; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMATURIA; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; KIDNEY FAILURE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NAUSEA; NONVENTILATOR HOSPITAL ASSOCIATED PNEUMONIA; OLIGURIA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 84901297379     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S25930     Document Type: Review

References (19)

1. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388-416.
2. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005;128(6):3854-3862.
3. Masterton RG, Galloway A, French G, etal. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 2008;62(1):5-34.
4. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165(7):867-903.
5. Davis J, Finley E. Focus on Infection Prevention. The breadth of hospital-acquired pneumonia: nonventilated versus ventilated patients in Pennsylvania. Pennsylvania Patient Safety Advisory. 2012;9(3):99-106.
6. Esperatti M, Ferrer M, Theessen A, etal. Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med. 2010;182(12):1533-1539.
7. Yang YS, Lee YT, Huang TW, etal. Acinetobacter baumannii nosocomial pneumonia: is the outcome more favorable in non-ventilated than ventilated patients? BMC Infect Dis. 2013;13:142.
8. Bousbia S, Papazian L, Saux P, etal. Repertoire of intensive care unit pneumonia microbiota. PLoS One. 2012;7(2):e32486.
9. Weber DJ, Rutala WA, Sickbert-Bennett EE, Samsa GP, Brown V, Niederman MS. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol. 2007;28(7):825-831.
10. Bhavnani SM, Rubino CM, Hammel JP, etal. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother. 2012;56(2):1065-1072.
11. Sopena N, Sabrià M. Multicenter study of hospital-acquired pneumonia in non-ICU patients. Chest. 2005;127(1):213-219.
12. Lunde CS, Hartouni SR, Janc JW, Mammen M, Humphrey PP, Benton BM. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother. 2009;53(8):3375-3383.
13. Lunde CS, Rexer CH, Hartouni SR, Axt S, Benton BM. Fluorescence microscopy demonstrates enhanced targeting of telavancin to the division septum of Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54(5):2198-2200.
14. Higgins DL, Chang R, Debabov DV, etal. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49(3):1127-1134.
15. Gotfried MH, Shaw JP, Benton BM, etal. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother. 2008;52(1):92-97.
16. Lodise TP Jr, Gotfried M, Barriere S, Drusano GL. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother. 2008;52(7):2300-2304.
17. Rubinstein E, Lalani T, Corey GR, etal. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin Infect Dis. 2011;52(1):31-40.
18. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard-Seventh Edition. M7-A7. Wayne, PA: CLSI; 2006. Available from: http://isoforlab.com/phocadownload/csli/M7-A7.pdf. Accessed April 3, 2014.
19. Saravolatz LD, Stein GE, Johnson LB. Telavancin: a novel lipoglycopeptide. Clin Infect Dis. 2009;49(12):1908-1914.